Early investigation of a novel SI306 theranostic prodrug for glioblastoma treatment

Glioblastoma multiforme (GBM) is one of the most aggressive malignancies with a high recurrence rate and poor prognosis. Theranostic, combining therapeutic and diagnostic approaches, arises as a successful strategy to improve patient outcomes through personalized medicine. Src is a non‐receptor tyro...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drug development research 2024-02, Vol.85 (1), p.e22158-n/a
Hauptverfasser:	Vagaggini, Chiara, Petroni, Debora, D'Agostino, Ilaria, Poggialini, Federica, Cavallini, Chiara, Cianciusi, Annarita, Salis, Annalisa, D'Antona, Lucia, Francesconi, Valeria, Manetti, Fabrizio, Damonte, Gianluca, Musumeci, Francesca, Menichetti, Luca, Dreassi, Elena, Carbone, Anna, Schenone, Silvia
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological activity Blood-Brain Barrier Cell Line Cell lines Gallium Gallium isotopes Glioblastoma Glioblastoma - diagnostic imaging Glioblastoma - drug therapy glioblastoma multiforme Glioma Humans Kinases Malignancy Permeability Pharmacokinetics Physiochemistry Precision Medicine Prodrugs Prodrugs - pharmacology Protein-tyrosine kinase receptors Radioisotopes Src inhibitors theranostic agents Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!